公开(公告)号：KR101361445B1

公开(公告)日：2014-02-12

申请号：KR1020110142340

申请日：2011-12-26

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K38/08 ,  A61K31/505 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/513 ,  A61K38/08 ,  A61K2300/00

Abstract: 본 발명은 서열번호 1의 서열을 가지는 WKYMVm 펩타이드를 포함하고, 5-플루오로우라실(5-fluorouracil) 및/또는 성숙수지상세포(mature dendritic cells)를 유효량 포함하는 암 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 약학적 조성물은 체내의 면역반응을 증진시켜 항암효과의 증진, 낮은 부작용, 높은 암의 전이 억제효과 등을 가진다.

公开(公告)号：KR1020130075934A

公开(公告)日：2013-07-08

申请号：KR1020110144262

申请日：2011-12-28

Applicant: 성균관대학교산학협력단

Inventor： 박석희 ,  이연숙 ,  배외식 ,  김성진

IPC: A61K38/10 ,  A61K38/16 ,  A61P31/00

CPC classification number: C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  A61K47/48038 ,  A61K47/542 ,  C07K1/1077

Abstract: PURPOSE: A pharmaceutical composition for treatment of sepsis including peptide originating from mad 6 burn (Smad6) as an active ingredient or the septic shock is provided to have an effect suppressing the expression and apoptosis phenomenon of the inflammatory cytokine is excellent. The effect increasing the degerm activation is excellent. CONSTITUTION: A peptide originating from the mad 6 burn (Smad6) having the amino acid sequence represented by the pharmaceutical composition for the treatment of the sepsis or the septic shock is the sequence number 1 is included to the active ingredient. The sepsis the toll - like receptor four times (TLR4) is activated. A method of curing the sepsis or the septic shock comprises the following step. The pharmaceutically effective dose of the pharmaceutical composition including the peptide originating from the mad 6 burn (Smad6) as an active ingredient is administered to entity.

Abstract translation: 目的：提供一种用于治疗败血症的药物组合物，其包括源自6号烧伤（Smad6）作为活性成分或脓毒性休克的肽，以具有抑制炎性细胞因子的表达和凋亡现象的效果。 增加去皮激活的效果非常好。 构成：具有由用于治疗败血症或败血性休克的药物组合物表示的氨基酸序列的源自疯狂6烧伤（Smad6）的肽是序列号1包括在活性成分中。 脓毒症四肢感染（TLR4）被激活。 治愈败血症或败血性休克的方法包括以下步骤。 药物组合物的药学有效剂量包括来源于疯狂6烧伤（Smad6）作为活性成分的肽给予实体。

公开(公告)号：KR1020130055043A

公开(公告)日：2013-05-28

申请号：KR1020110119149

申请日：2011-11-15

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  이하영 ,  배건호

IPC: C07K7/06 ,  A61K47/48

CPC classification number: C07K7/06 ,  A61K47/65 ,  A61K2123/00 ,  C12N2740/16122

Abstract: PURPOSE: A novel peptide is provided to promote intracellular calcium ion release through activation of phospholipase C and to act on leukocytes, and to promote reactive oxygen generation. CONSTITUTION: A peptide contains an amino acid sequence selected from the group consisting of sequence numbers 1-3. The peptide regulates activity of neutrophil. The peptide induces increase of intracellular calcium ions, stimulates cell chemotactic motion, and specifically acts on leukocytes. The peptide of sequence number 2 or 3 induces superoxide generation in human neutrophil. The peptide of sequence number 1 or 3 act on FPR1(formyl peptide receptor 1). The peptide of sequence number 2 act on FPR2(formyl peptide receptor 2). A pharmaceutical composition contains pharmaceutically effective amount of the peptide.

Abstract translation: 目的：提供一种新的肽，以通过活化磷脂酶C促进细胞内钙离子释放并作用于白细胞，并促进活性氧的产生。 构成：肽含有选自序列号1-3的氨基酸序列。 肽调节中性粒细胞的活性。 肽诱导细胞内钙离子的增加，刺激细胞趋化运动，并具体作用于白细胞。 序列号2或3的肽诱导人嗜中性粒细胞中的超氧化物产生。 序列号1或3的肽作用于FPR1（甲酰肽受体1）。 序列号2的肽作用于FPR2（甲酰肽受体2）。 药物组合物含有药学有效量的肽。

公开(公告)号：KR1020120106248A

公开(公告)日：2012-09-26

申请号：KR1020110024239

申请日：2011-03-18

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  김상두

IPC: A61K31/18 ,  A61P29/00 ,  A61P31/04

CPC classification number: A61K31/18 ,  A23L33/10 ,  A23V2002/00 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/192 ,  A61K47/20 ,  A23V2200/324

Abstract: PURPOSE: A composition containing m-3M3FBS or pharmaceutically acceptable salt thereof is provided to suppress LPS-related signal transduction and to effectively prevent or treat inflammatory or infectious diseases. CONSTITUTION: A composition for preventing or treating inflammatory diseases or infectious disease contains m-3M3FBS of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The active ingredient is an activator of phospholipase C. The composition additionally contains a carrier, excipient, or diluent. The composition is alternately used with an anti-inflammatory agent, antipyretic, analgesic, antibiotics, antibacterial agent, or anti-allergic agent.

Abstract translation: 目的：提供含有m-3M3FBS或其药学上可接受的盐的组合物以抑制LPS相关信号转导并有效预防或治疗炎性或感染性疾病。 构成：用于预防或治疗炎性疾病或感染性疾病的组合物含有化学式1的m-3M3FBS或其药学上可接受的盐作为活性成分。 活性成分是磷脂酶C的活化剂。该组合物另外含有载体，赋形剂或稀释剂。 该组合物交替使用抗炎剂，解热药，止痛剂，抗生素，抗菌剂或抗过敏剂。

公开(公告)号：KR101175099B1

公开(公告)日：2012-08-21

申请号：KR1020100047982

申请日：2010-05-24

Applicant: 성균관대학교산학협력단

Inventor： 배외식 ,  이하영

IPC: C07K7/08 ,  A61K38/10 ,  A61P35/00 ,  A61P37/00

Abstract: 본발명은포르밀펩타이드수용체 2의세포내 루프 3 구역의펩타이드서열에팔미트산을결합시킨리간드를제공한다. 본발명의새로운 FPR2 리간드를통해백혈구의면역반응을효과적으로증진시킴으로써감염, 염증치료및 항암치료를위한새로운치료제가제공된다.